Table 5.
Exosomal miRNAs as predictor biomarkers for therapeutic efficacy in DLBCL.
| Study | Exosomal miRNAs | Sample | Source | Exosome isolation | miRNA Profiling | Result |
|---|---|---|---|---|---|---|
| Exosomal miRNAs with significant differential expressed | ||||||
| Feng et al., 2019 (20), | miR-125b-5p miR-99a-5p | 116 DLBCL patients (33 chemoresistant group vs. 83 chemosensitive group) | serum | ExoQuick | RNA seq qRT-PCR | Upregulation in chemoresistant group versus chemosensitive group: ↑ R-CHOP resistance |
| Zare et al., 2019 (21), | miR-155 | 48 DLBCL patients (16 refractory/relapsed patients vs. 32 responsive/receiving R-CHOP patients) | plasma | ExoSpin | qRT-PCR | Upregulation in refractory/relapsed patients versus responsive/receiving R-CHOP patients: ↓ response to R-CHOP therapy |
| miR-let-7g | Downregulation in patients receiving R-CHOP versus refractory/relapsed patients: ↓ response to R-CHOP therapy | |||||
| Xiao et al., 2019 (15), | miR-451a | 89 DLBCL patients treated with the R-CHOP regimen vs. 48 controls | serum | ExoQuick | qRT-PCR | Upregulation after treatment: biomarkers for prediction response to R-CHOP regimen |
| Exosomal miRNAs with insignificant differential expressed | ||||||
| Feng et al., 2019 (20), | miR-10a-5p miR-10b-5p | 116 DLBCL patients (33 chemoresistant group vs. 83 chemosensitive group) | serum | ExoQuick | RNA seq qRT-PCR | No significant difference between the two groups |
| Zare et al., 2019 (21), | miR-let-7i | 48 DLBCL patients (16 refractory/relapsed patients vs. 32 responsive/receiving R-CHOP patients) | plasma | ExoSpin | qRT-PCR | No significant difference between the two groups |
| Zare et al., 2019 (18), | miR-146a | 48 DLBCL patients (16 refractory patients vs. 32 responsive/receiving R-CHOP patients) | plasma | Exospin | qRT-PCR | No significant difference between the two groups |
DLBCL, Diffuse large B-cell lymphoma; miR, microRNA; qRT-PCR, quantitative-Real time polymerase chain reaction; RNA seq, RNA sequencing; R-CHOP, Cyclophosphamide, adriamycin, vincristine, and prednisone, combined with rituximab; ↑, Increased; ↓, Decreased.